Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4UXT1)

Drug Name
tyramine Drug Info
Synonyms
Tyramine; 4-(2-Aminoethyl)phenol; 51-67-2; 4-Hydroxyphenethylamine; p-Tyramine; 2-(4-Hydroxyphenyl)ethylamine; Uteramine; Tyramin; Tyrosamine; Tocosine; 4-Hydroxyphenylethylamine; Systogene; Phenol, 4-(2-aminoethyl)-; p-Hydroxyphenethylamine; Tenosin-wirkstoff; p-Hydroxyphenylethylamine; p-(2-Aminoethyl)phenol; 2-(p-Hydroxyphenyl)ethylamine; Phenethylamine, p-hydroxy-; p-beta-Aminoethylphenol; Phenol, p-(2-aminoethyl)-; Benzeneethanamine, 4-hydroxy-; Tyramine base; beta-Hydroxyphenylethylamine; NSC 249188; p-tyramine; [3H]tyramine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5610
ChEBI ID
CHEMBL11608
CAS Number
CAS 51-67-2
TTD Drug ID
DM4UXT1
VARIDT Drug ID
DR01389
INTEDE Drug ID
DR2043

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Trace amine-associated receptor-1 (TAAR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amphetamine DMSZQAK Attention deficit hyperactivity disorder 6A05.Z Approved [5]
Lisdexamfetamine DM6W8V5 Attention deficit hyperactivity disorder 6A05.Z Approved [6]
Dextroamphetamine DMMIHVP Attention deficit hyperactivity disorder 6A05.Z Approved [5]
Hydroxyamphetamine Hydrobromide DMQSGM0 Horner syndrome 8D8A.1 Approved [7]
SEP-363856 DMG2QP4 Schizophrenia 6A20 Phase 3 [8]
NT0202 DMCMIJ1 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [5]
SPD-465 DM7NV1I Attention deficit hyperactivity disorder 6A05.Z Phase 3 [5]
RG-7351 DMFGR98 Major depressive disorder 6A70.3 Phase 1 [9]
EPPTB DMK3VID Discovery agent N.A. Investigative [10]
R(-)amphetamine DM72ES1 Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic cation transporter 1 (SLC22A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [12]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [13]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [14]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [15]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [3]
Verapamil DMA7PEW Angina pectoris BA40 Approved [16]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [17]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [18]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [19]
Propranolol DM79NTF Angina pectoris BA40 Approved [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Copper amine oxidase (AOC3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tresperimus DMOVBSF Autoimmune diabetes 5A10 Discontinued in Phase 3 [21]
PHENETHYLAMINE DMX0G4F Discovery agent N.A. Investigative [4]
Benzylamine DMRM6ES N. A. N. A. Investigative [4]
Methylamine DMTPL4W N. A. N. A. Investigative [4]
Drug(s) Metabolized By Semicarbazide-sensitive amine oxidase (AOC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PHENETHYLAMINE DMX0G4F Discovery agent N.A. Investigative [4]
Benzylamine DMRM6ES N. A. N. A. Investigative [4]
Methylamine DMTPL4W N. A. N. A. Investigative [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Trace amine-associated receptor-1 (TAAR1) TTIU98M TAAR1_HUMAN Agonist [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Copper amine oxidase (AOC3) DE6SOC5 AOC3_HUMAN Substrate [4]
Semicarbazide-sensitive amine oxidase (AOC2) DE8DP90 AOC2_HUMAN Substrate [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2148).
2 Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. PLoS One. 2011;6(10):e27073.
3 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
4 The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. Cell Mol Life Sci. 2009 Aug;66(16):2743-57.
5 Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
6 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
7 Diagnostic pharmacology of the pupil.Clin Neuropharmacol.1985;8(1):27-37.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of Roche.
10 The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6.
11 The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007 Oct;6(7):628-39.
12 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
13 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
14 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
15 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
16 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
17 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
18 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
19 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
20 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
21 Metabolism of tresperimus by rat aorta semicarbazide-sensitive amine oxidase (SSAO). Fundam Clin Pharmacol. 2002 Dec;16(6):461-70.